Filter posts

PTAB, IPRs and Uncertainty in the Patent System

The topic of inter partes reviews (IPRs) has dominated conversation in patent circles for the …

BIO's Statement Regarding SCOTUS Patent Review Decision

BIO issued the following statement following yesterday’s Supreme Court decision in the case of Cuozzo …

Will the PTAB Be A Roadblock for Biotech? Stories from Sessions at BIO 2016

We’re at the beginning of day 3 here at BIO 2016, and that means we’ve already had …

IP Sessions at BIO 2016--Come Join us in San Francisco!

That’s right, we’re back at it again! This year’s BIO International Convention will host several innovative …

Life Sciences Roundtable Event Addressed the Value of Innovation

Yesterday, BIO’s Jeanne Haggerty, Senior Vice President for Federal Government Relations, participated in a roundtable …

Join us for the IP Symposium at the 2016 BIO World Congress!

Ah, San Diego. What is it they say about you? Come for the beaches…. Stay …

NIH Office of Science Policy Unveils New Resources

The NIH Office of Science Policy (OSP) works on a wide range of issues including …

Judd Gregg: Biodefense Funding Is Crucial to National Security

Writing in the Morning Consult, former Senator Judd Gregg explains critical role of federal programs …

What We’ll Be Talking about at the BIO Spring IPCC Conference

It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee …

"II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys …